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Abstract
Peptide nucleic acid (PNA) is known to bind with extraordinarily high affinity and sequence-specificity to complementary
nucleic acid sequences and can be used to suppress gene expression. However, effective delivery into cells is a major
obstacle to the development of PNA for gene therapy applications. Here, we present a novel method for the in vitro delivery
of antigene PNA to cells. By using a nucleocapsid protein derived from Simian virus 40, we have been able to package PNA
into pseudovirions, facilitating the delivery of the packaged PNA into cells. We demonstrate that this system can be used
effectively to suppress gene expression associated with multidrug resistance in cancer cells, as shown by RT-PCR, flow
cytometry, Western blotting, and cell viability under chemotherapy. The combination of PNA with the SV40-based delivery
system is a method for suppressing a gene of interest that could be broadly applied to numerous targets.
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Introduction
The effectiveness of chemotherapeutic agents is often limited by
various mechanisms that exist in cancer cells, often through
overexpression of certain genes, in particular those coding for
membrane-spanning ATP-binding cassette (ABC) transporters;
examples include MDR1 [1], ABCG2 [2–4], and MRP1 [5]. The
MDR1 gene is frequently overexpressed in several drug-resistant
cancers, such as acute myeloid leukemia [6,7], colon cancer [8],
adrenal cancer [9], and kidney cancer [10]. An over-abundance of
P-glycoprotein (P-gp), the protein product of the MDR1 gene [1],
leads to multidrug resistance (MDR), because cancer cells become
able to efflux a number of structurally diverse compounds
including many chemotherapy agents, such as paclitaxel [11,12],
doxorubicin [13], and vinblastine [14]. Silencing the expression of
genes such as MDR1 is one potential way to address the problem
of MDR in cancer.
Peptide nucleic acid (PNA) is a synthetic DNA analog in which
the sugar-phosphate backbone is replaced with a polyamide
backbone [15,16]. The nucleobases covalently attached to the
PNA backbone enable the PNA oligomers to bind to comple-
mentary DNA or RNA sequences via Watson-Crick base-pairing.
Certain key properties of PNA make it ideal to target DNA or
RNA sequences in vivo [17]. First, because PNA is purely synthetic,
it is resistant to degradation by nucleases and proteases [18], and
thus these molecules may remain in cells for extended time periods
[19]. Second, the thermal stability of PNA:oligonucleotide
complexes is significantly higher than corresponding oligonucle-
otide duplexes. This high stability when bound to its target
oligonucleotide should enhance the ability of PNA to suppress
protein or gene expression. Numerous studies have sought to
develop PNA as an antisense agent to suppress protein expression
by targeting an mRNA sequence [20]. In this way, PNA inhibits
translation by sterically blocking translation start sites along
mRNA [21]. More recently, PNA has been used as an antigene
agent that suppresses gene expression by targeting a DNA
sequence [22]. The work of the Corey group [23] has elegantly
demonstrated that PNA designed to target the transcription
initiation sites of genes may effectively suppress overall expression;
by targeting the transcription start site of the gene, the whole gene
is inhibited, including all splicing forms of the protein, making
antigene PNA a powerful inhibitor.
To date, only a few genes have been targeted using this
approach. A key hurdle in the development of PNA as an antisense
or antigene agent is the effective delivery of PNA to cells [24].
While some cellular systems are permeable to PNA, many cells
lines are not [15,17,21], so various systems have been developed to
deliver PNA to cells. Most of these systems involve covalent
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into a cell, such as a lipid or cell-penetrating peptide [22,25–30].
Others chemically modify the PNA backbone with multiple
arginine side chains to gain entry [31]. Unfortunately, there is no
delivery system currently available that works with all cells.
Therefore, a universally applicable system could facilitate the
therapeutic use of PNA.
To that end, we investigated the simian virus 40 (SV40) in vitro-
packaging (IVP) system, in which pseudovirions are formed when
the major capsid protein of SV40 (VP1) self-assembles around
nucleic acids [32,33]. Unlike other in-vitro packaging systems, no
viral genetic material or packaging signal sequence is required to
form these pseudovirions. To date, SV40 pseudovirions have been
shown to deliver reporter genes such as GFP, suicide genes such as
Pseudomonas exotoxin, plasmids encoding shRNA, and siRNA
oligomers [34,35]. These pseudovirions can transduce both
dividing and quiescent cells in vitro and tissues in vivo. Therefore,
we chose the SV40 system to deliver PNA molecules to cancer
cells.
Here we demonstrate the effectiveness of the SV40 IVP system
to deliver antigene PNA molecules against the MDR1 gene
through the reduction of the expression of MDR1 at the
transcriptional level leading to reduced total levels of P-gp within
a cell. These changes result in a decreased ability of the cell to
efflux xenobiotic compounds (efflux capacity). Additionally, drug-
resistant cells transduced with PNA targeted against the MDR1
gene and treated with the chemotherapeutic agent paclitaxel were
significantly less viable compared to those transduced with a
scrambled sequence of PNA. Our in vitro results suggest that
delivery of PNA via the SV40 delivery system would be a
promising technique to treat certain cancers that exhibit MDR1-
mediated MDR.
Results and Discussion
Antigene PNA silences MDR1 mRNA transcription
A scrambled PNA sequence (S), and an antigene PNA (P)
designed to bind to a sequence in the vicinity (22t o+13) of the
major transcription start site of MDR1 were designed. The stated
position of P is relative to the major +1 transcription start site (nt
87,230,200 of the NCBI Reference Sequence NC_000007.13) of
the MDR1 gene as described by Ueda et al. [36]. A detailed
BLAST summary of the two sequences indicates that P maps only
to the MDR1 gene with 100% coverage while S does not map to
any coding transcript with 100% coverage. After synthesis and
purification by reverse-phase high performance liquid chroma-
tography, the identity of the PNAs was confirmed by mass
spectroscopy and the melting temperatures of complementary
PNA:DNA duplexes were determined (Table 1). The KB-8-5 cell
line was chosen for subsequent analysis because it is a human KB
carcincoma cell line that is known to overexpress P-gp and is thus
resistant to a variety of chemotherapeutic agents.
We first sought to measure how efficient the antisense PNA
molecules were at blocking the transcription of the MDR1 gene by
measuring the MDR1 mRNA levels in KB-8-5 cells transduced
with P and S via the SV40 delivery system. The mRNA levels
were quantified using RT-PCR 24 hr and 48 hr post transduction
and normalized to the housekeeping gene GAPDH. A slight
increase was observed after 24 hr (p.0.1), but a significant
reduction (33%, p,0.05) in MDR1 mRNA levels was observed
48 hr post-transduction in cells transduced with P as compared to
those transduced with S (Figure 1). Because a significant decrease
was observed at 48 hr, this time-point was chosen for subsequent
experiments.
Table 1. PNA Sequences, Melting Temperatures, and Mass
Spectroscopy Characterization.
PNA Sequence Tma (6C) Molecular Weight
b
Calculated Observed
P AcNH-TCA TTC GAG
TAG CGG-Lys-CONH2
76.5 4288.1 4288.3
S AcNH-TAC GTC ATC
TCG CAG-Lys-CONH2
72.0 4208.1 4207.5
Ac=acetyl group.
aTm represents the melting temperature for the duplex formed between the
indicated PNA and antiparallel DNA. Conditions for Tm measurement were as
follows: 3.0 mM of PNA:DNA duplex, 150 mM NaCl, 10 mM sodium phosphate
buffer, pH 7.0, 0.1 mM EDTA, UV measured at 260 nm from 95 to 25uC, in 1uC
increments. All values are averages from two or more experiments.
bAccurate mass Electrospray Ionization (ESI) mass spectra were obtained on a
Waters LCT Premier time-of-flight (TOF) mass spectrometer. The instrument
was operated in W-mode at a nominal resolution of 10000. The electrospray
capillary voltage was 2 KV and the sample cone voltage was 60 volts. The
desolvation temperature was 275uC and the desolvation gas was nitrogen with
a flow rate of 300 L/hr. Accurate masses were obtained using a standard
internal reference. The sample was introduced into the mass spectrometer via
a direct loop injection. Both positive and negative ion accurate mass data were
achieved simply by reversing the instrument’s operating polarity.
Deconvolution of multiply charged ions was performed with MaxEnt I.
doi:10.1371/journal.pone.0017981.t001
Figure 1. MDR1 mRNA levels in KB-8-5 cells 24 hr and 48 hr
post transduction with IVP-scrambled (S) or IVP-antigene PNA
(P). MDR1 mRNA levels were normalized by GAPDH levels, and are
reported relative to the MDR1 mRNA level of cells transduced with S,
24 hr post transduction. A significant difference (*, p,0.05) was
observed between P and S at 48 hr post transduction. Error bars
represent the standard deviation from the average of three experi-
ments.
doi:10.1371/journal.pone.0017981.g001
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or P-gp Western blotting assays
P and S were tested for potential non-specific effects on the
efflux assay by adding the same quantity of naked PNA used in a
packaging reaction directly to untransduced cells and then
performing the assay as described. Analysis confirmed that these
PNAs do not interfere with the measurement of efflux capacity
(data not shown). The PNAs were also tested for their effect on
Western blotting assays. Analysis of the intensities of the bands by
ImageJ demonstrated that there was less than 1% difference when
PNA was added to cell lysate directly before loading, indicating
that Western blotting is an acceptable method for analyzing PNA-
mediated reduction of total P-gp expression (data not shown).
P-gp expression and function are reduced in cells
transduced with antigene PNA
We sought to test whether the decreased MDR1 mRNA levels
affected P-gp expression and its efflux function. To that end, KB-
8-5 cells were transduced with P and S via the SV40 delivery
system and harvested 48 hr post-transduction. A 35% reduction in
total P-gp levels (p,0.01) by Western blotting was observed for
cells transduced with P as compared to cells transduced with S
(Figure 2). This result is the average of four independent
experiments. The function of P-gp was measured by efflux of
Rhodamine 123 48 hr post-transduction using flow cytometry. An
accumulation of Rhodamine 123 results in higher intracellular
fluorescence, indicating a reduction in cellular efflux capacity.
Relative to cells transduced with S, cells transduced with P via the
SV40 delivery system exhibited 38% greater fluorescence
(Figure 3).
Transducing cells twice using IVP-antigene PNA (P) does
not substantially reduce total expression or function of
P-gp
On the first day of the experiment (Day 1), KB-8-5 cells were
transduced with P via the SV40 delivery system. On Day 4, the
cells were trypsinized, and 1610
5 cells were re-transduced. These
cells were then analyzed on Day 6 by flow-cytometry and Western
blotting as described in Materials and Methods. As a control, KB-
8-5 cells transduced with P only during the first transduction on
Day 1 were also analyzed. P-gp expression was further reduced by
15% (p,0.05) while efflux capacity was reduced by 13% (p,0.05)
(data not shown) in cells transduced twice versus once. Although
statistically significant, transducing twice is only a slight improve-
ment over a single transduction.
KB-8-5 cells are more susceptible to paclitaxel when
transduced with antigene PNA
In order to assess the resistance of P-gp-expressing cells to
chemotherapy drugs after transduction with antigene PNA, KB-8-
5 cells were transduced with P and S as described in Materials and
Methods. One day post-transduction, the medium was replaced by
growth media containing paclitaxel (400 ng/ml), a known P-gp
substrate. The concentration of viable cells was calculated every 2–
3 days (Figure 4). By day 15, a 32% reduction in the number of
viable cells was observed for cells transduced with P relative to
those transduced with S. The experiment was repeated twice,
independently, with similar results. As a control, cells transduced
with S were also grown in growth media without paclitaxel.
Efficiency of the SV40 delivery system
The greatest obstacle in the development of antisense or
antigene PNA for therapeutic use is efficient delivery into cells.
The in vitro delivery of PNA accomplished by Corey and colleagues
[23] used a liposome-based system that packaged DNA/PNA
complexes. Although protein expression was inhibited using
200 nM concentrations of DNA/PNA, multiple transductions
were used. Another strategy that has been employed to deliver
PNAs into cells is to use antisense or antigene PNA-peptide
conjugates, which have several positively charged amino acids
linked to the N-terminus of the PNA [22,28,37,38]. These
conjugates were shown to effectively silence a protein product,
although PNA concentrations between 1–10 mM were needed,
similar to the concentrations used in this report. Another strategy
reported in the literature to boost the inhibitory effect of PNA-
peptide conjugates was to add calcium ions [30] or chloroquine
[38,39], which aids in endosome disruption, to the media. These
agents improved the potency of PNA-peptide conjugates but also
increased cell death [28].
One of the most significant advantages of the SV40 delivery
system used in our studies is the high efficiency with which these
pseudovirion particles deliver constructs to a broad range of cells
[40,41]. Our studies demonstrate that MDR1 can be silenced at
the transcriptional level in vitro by antigene PNA delivered via the
SV40 system. We showed that SV40 pseudovirions carrying PNA
molecules designed to bind in the region of the major transcription
initiation site of the MDR1 gene [36] could effectively decrease
MDR1 mRNA levels and decrease P-gp-mediated efflux capacity
in drug-resistant KB-8-5 cells. Significantly, antigene PNA
delivered via the SV40 system increased the sensitivity of KB-8-
5 cells to a chemotherapeutic agent, a requirement for an effective
treatment for P-gp-mediated drug resistance.
In two previous studies [42,43], antisense PNA was used to
knockdown P-gp expression in vitro, with results comparable to
Figure 2. Total P-gp expression in KB-8-5 cells transduced with
IVP-scrambled (S) or IVP-antigene PNA (P) was measured by
Western blotting using the P-gp specific monoclonal antibody
C219; b-actin served as a loading control. The graph represents an
average of 4 independent experiments; error bars represent the
standard error of the mean. Quantification of P-gp band intensities
was performed using ImageJ.
doi:10.1371/journal.pone.0017981.g002
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designed to be complementary to a sequence encompassing the
translation start site (29t o+6) of the MDR1 mRNA, and the PNA
was either added directly to the cell culture media, or hybridized
to DNA and delivered using a lipid-based transfection reagent.
Similar to the findings presented here, treating cells with
micromolar concentrations of antisense PNA yielded almost a
30% reduction in MDR1 mRNA levels and increased the cells’
sensitivity to the chemotherapeutic agent adriamycin. In contrast
to those studies, our antigene PNA delivered using the SV40
system required much shorter exposures to PNA; transduction
times in our study were 2.5 hr, compared to 48 or 96 hr in the
antisense studies. Although in the experiments presented here the
plates were not aspirated after transduction to remove excess
packaged PNA still in the media, our experience has shown that
replacing the media after transduction does not significantly alter
transduction efficiency. Also, we found that transducing cells
multiple times did not significantly increase the silencing effect of
the PNA molecules while previous studies using the SV40 system
to deliver DNA [44,45] showed that there was an advantage to
multiple transductions.
Materials and Methods
Cell culture
The P-gp-expressing, drug-resistant human KB carcinoma cell
line KB-8-5 [46] was grown as a monolayer culture at 37uCi n5 %
CO2 using growth media comprised of Dulbecco’s modified
Eagle’s medium (DMEM) supplemented with 10% FBS, 1.8 mM
L-glutamine, 90 units/ml penicillin, 90 mg/ml streptomycin, and
10 ng/ml colchicine.
Synthesis of PNA molecules
PNA was synthesized using standard Boc chemistry as described
previously [47,48]. Methyl benzhydryl amine (MBHA) resin
(1.0 g, 0.3 mmol active sites/gram) was downloaded to
0.1 mmol/g with Boc-Lys-(2-Cl-Z)-OH using HATU and DIEA.
Any remaining active sites were then capped with a solution of
Ac2O:NMP:pyridine. Downloaded resin (50 mg) was deprotected
with 5% m-cresol in TFA, followed by PNA coupling using a
0.4 M solution of PNA monomer in NMP pre-mixed with 0.8 M
MDCHA in pyridine and 0.2 M HBTU in DMF. Following
coupling, the resin was drained under vacuum and washed and
free sites were capped with a mixture of Ac2O: NMP: pyridine.
This cycle was then repeated iteratively until the oligomer was
complete on the resin. Cleavage from the resin is accomplished
under acidic conditions at 0uC using thioanisole, m-cresol,
TFMSA, and TFA. Crude product is obtained by repeated
Figure 3. KB-8-5 cells were transduced with IVP-scrambled (S) or IVP-antigene PNA (P) and the P-gp-mediated efflux capacity was
measured through the efflux of the fluorescent dye Rhodamine 123 (Rh123), in the presence or absence of a P-gp inhibitor,
cyclosporin A (CsA). The coincident histograms of cells transduced with S or P and treated with CsA demonstrate effective P-gp inhibition. In the
absence of inhibitor, cells transduced with P show a significant decrease in efflux capacity, evidenced by greater intracellular fluorescence, as
compared to cells transduced with S.
doi:10.1371/journal.pone.0017981.g003
Figure 4. KB-8-5 cells were transduced with IVP-scrambled (S)
or IVP-antigene PNA (P) and media containing the chemother-
apeutic paclitaxel (400 ng/ml) was added one day post-
transduction. Cells were trypsinized every 2–3 days, resuspended in
a set volume of media, and counted with Trypan blue. The
concentration of viable cells is plotted as a function of time. Error bars
represent the standard error of the mean of three replicate counts.
doi:10.1371/journal.pone.0017981.g004
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final product is purified by reverse phase HPLC.
Preparation of in vitro-packaged (IVP) PNA vectors and
creation of pseudovirions
Packaging of vectors in this study was performed using scaled-
up production methods as previously described [44]. One
packaging reaction consisted of VP1-containing nuclear extract
from Sf9 cells (100 mg, see Methods S1), which was incubated
along with either the MDR1-targeted antigene PNA (P) or the
scrambled control (S) (see Table 1) in the presence of 5 mM ATP
and 8 mM MgCl2 at 37uC for 6 hr in a 600 mL reaction volume to
form pseudoviral particles. The PNA concentration during
packaging was 25.2 mM. Following incubation, 10 mM CaCl2
was added to the reaction tube (0.9 mM final concentration),
which was then incubated on ice for 1 hr. In vitro-packaged PNA
(IVP-PNA) was stored at 220uC.
Transduction of KB-8-5 cells with IVP-PNA
KB-8-5 cells (1610
5) were plated in 60 mm dishes 24 hr prior
to transduction in 4 ml of DMEM supplemented with 10% FBS
and 1.8 mM L-glutamine (transduction media). On the day of the
transduction, the medium was aspirated from the dishes and
replaced with 750 ml of fresh transduction media along with 660 ml
(one full reaction) of the IVP-PNA. The final concentration of
IVP-PNA during the transduction was 10.7 mM. Cells were placed
on a rotary shaker at 30 rpm for 2.5 hr at 37uCi n5 %C O 2. Four
ml of transduction media was added post-transduction, decreasing
the effective PNA concentration more than 5-fold, and the plates
were returned to the incubator until analyzed.
RNA analysis of transduced KB-8-5 cells to measure P-gp
mRNA expression
RNA was isolated from KB-8-5 cells 24 hr and 48 hr post-
transduction using the Qiagen RNeasy Kit per the manufacturer’s
protocol with a 15-minute on-column DNAse incubation step.
The concentration of RNA was measured with a Nanodrop ND-
1000 Spectrophotometer. For each experiment, duplicate mea-
surements of the MDR1 mRNA level were made by real-time
quantitative RT-PCR using a TaqMan Gene Expression Assay
(Assay ID Hs00184491_m1, Applied Biosystems). MDR1 mRNA
levels were normalized to GAPDH (Assay ID Hs99999905_m1,
Applied Biosystems).
Measurement of P-gp-mediated efflux capacity by flow
cytometry
KB-8-5 cells were transduced with IVP-PNA as described above
and harvested 48 hr post transduction. To assess the efflux
capacity of cells transduced with IVP-PNA, cells were incubated
with the fluorescent compound Rhodamine 123 (0.5 mg/ml,
Sigma) in the presence or absence of 10 mM cyclosporin A
(Sigma), a known P-gp inhibitor. Intracelluar fluorescence was
then analyzed with a FACScalibur
TM (BD Biosciences) flow
cytometer running CellQuest
TM software (BD Biosciences). Details
about incubation times and washing conditions are provided in
Methods S1.
Analysis of total P-gp using SDS-PAGE Western blot
KB-8-5 cells were transduced as described above and lysed
48 hr post-transduction. Proteins in the whole-cell lysates were
separated by denaturing SDS-PAGE and P-gp was identified by
Western blotting with the primary antibody C219 (Fujirebio
Diagnostic). Band intensities were quantified using ImageJ
(National Institutes of Health). Specific conditions used for lysis
and Western band detection are provided in Methods S1.
Viability assay
KB-8-5 cells were plated in transduction media and transduced
as described above. One day post-transduction, transduction
media was replaced with growth media containing 400 ng/ml
paclitaxel (Sigma) and the cells were transferred to a T-75 flask
(Corning). Every 2–3 days the cells were trypsinized and
resuspended in a set volume of media. Live cells were counted
using Trypan Blue stain (0.4%; Invitrogen), and then replated into
a T-75 flask. The assay was stopped after 15 days.
Supporting Information
Methods S1 Supplemental materials and methods.
(DOC)
Acknowledgments
The authors thank Dr. Di Xia and Mr. George Leiman for their help in the
preparation of this manuscript.
Author Contributions
Conceived and designed the experiments: PEL DHA CKS. Performed the
experiments: BM NZ PEL AHM MO. Analyzed the data: MMG DHA
CKS. Contributed reagents/materials/analysis tools: MMG DHA CKS.
Wrote the paper: BM PEL DHA CKS.
References
1. Gottesman MM, Fojo T, Bates SE (2002) Multidrug resistance in cancer: role of
ATP-dependent transporters. Nat Rev Cancer 2: 48–58.
2. Doyle LA, Ross DD (2003) Multidrug resistance mediated by the breast cancer
resistance protein BCRP (ABCG2). Oncogene 22: 7340–7358.
3. Doyle LA, Yang W, Abruzzo LV, Krogmann T, Gao Y, et al. (1998) A
multidrug resistance transporter from human MCF-7 breast cancer cells. Proc
Natl Acad Sci USA 95: 15665–15670.
4. Miyake K, Mickley L, Litman T, Zhan Z, Robey R, et al. (1999) Molecular
cloning of cDNAs which are highly overexpressed in mitoxantrone-resistant
cells: demonstration of homology to ABC transport genes. Cancer Res 59: 8–13.
5. Szakacs G, Paterson JK, Ludwig JA, Booth-Genthe C, Gottesman MM (2006)
Targeting multidrug resistance in cancer. Nat Rev Drug Discov 5: 219–
234.
6. Chitnis M, Hegde U, Chavan S, Juvekar A, Advani S (1991) Expression of the
multidrug transporter P-glycoprotein and in vitro chemosensitivity: correlation
with in vivo response to chemotherapy in acute myeloid leukemia. Select Cancer
Ther 7: 165–173.
7. te Boekhorst PA, de Leeuw K, Schoester M, Wittebol S, Nooter K, et al. (1993)
Predominance of functional multidrug resistance (MDR-1) phenotype in CD34+
acute myeloid leukemia cells. Blood 82: 3157–3162.
8. Hotta T, Tanimura H, Iwahashi M, Tani M, Tsunoda T, et al. (1999) P-
glycoprotein-expressing tumor cells are resistant to anticancer drugs in human
gastrointestinal cancer. Surgery Today 29: 591–596.
9. Fojo AT, Ueda K, Slamon DJ, Poplack DG, Gottesman MM, et al. (1987)
Expression of a multidrug-resistance gene in human tumors and tissues. Proc
Natl Acad Sci USA 84: 265–269.
10. Fojo AT, Shen DW, Mickley LA, Pastan I, Gottesman MM (1987) Intrinsic drug
resistance in human kidney cancer is associated with expression of a human
multidrug-resistance gene. J Clin Oncol 5: 1922–1927.
11. Ambudkar SV, Kimchi-Sarfaty C, Sauna ZE, Gottesman MM (2003) P-
glycoprotein: from genomics to mechanism. Oncogene 22: 7468–7485.
12. Hille S, Rein DT, Riffelmann M, Neumann R, Sartorius J, et al. (2006)
Anticancer drugs induce mdr1 gene expression in recurrent ovarian cancer.
Anti-Cancer Drug 17: 1041–1044.
Inhibiting Multidrug Resistance by PNAs
PLoS ONE | www.plosone.org 5 March 2011 | Volume 6 | Issue 3 | e1798113. Shen F, Chu S, Bence AK, Bailey B, Xue X, et al. (2008) Quantitation of
doxorubicin uptake, efflux, and modulation of multidrug resistance (MDR) in
MDR human cancer cells. J Pharmacol Exp Ther 324: 95–102.
14. Warner E, Tobe SW, Andrulis IL, Pei Y, Trachtenberg J, et al. (1995) Phase I-II
study of vinblastine and oral cyclosporin A in metastatic renal cell carcinoma.
Amer J Clin Oncol 18: 251–256.
15. Corradini R, Sforza S, Tedeschi T, Totsingan F, Marchelli R (2007) Peptide
nucleic acids with a structurally biased backbone: effects of conformational
constraints and stereochemistry. Curr Top Med Chem 7: 681–694.
16. Nielsen PE, Egholm M, Berg RH, Buchardt O (1991) Sequence-selective
recognition of DNA by strand displacement with a thymine-substituted
polyamide. Science 254: 1497–1500.
17. Koppelhus U, Nielsen PE (2003) Cellular delivery of peptide nucleic acid (PNA).
Adv Drug Deliv Rev 55: 267–280.
18. Demidov VV, Potaman VN, Frankkamenetskii MD, Egholm M, Buchard O,
et al. (1994) Stability of peptide nucleic acids in human serum and cellular
extracts. Biochem Pharmacol 48: 1310–1313.
19. Chiarantini L, Cerasi A, Fraternale A, Andreoni F, Scari S, et al. (2002)
Inhibition of Macrophage iNOS by Selective Targeting of Antisense PNA.
Biochemistry 41: 8471–8477.
20. Larsen HJ, Bentin T, Nielsen PE (1999) Antisense properties of peptide nucleic
acid. Biochim Biophys Acta 1489: 159–166.
21. Chiarantini L, Cerasi A, Fraternale A, Millo E, Benatti U, et al. (2005)
Comparison of novel delivery systems for antisense peptide nucleic acids.
J Control Release 109: 24–36.
22. Kaihatsu K, Huffman KE, Corey DR (2004) Intracellular uptake and inhibition
of gene expression by PNAs and PNA-peptide conjugates. Biochemistry 43:
14340–14347.
23. Janowski BA, Kaihatsu K, Huffman KE, Schwartz JC, Ram R, et al. (2005)
Inhibiting transcription of chromosomal DNA with antigene peptide nucleic
acids. Nat Chem Biol 1: 210–215.
24. Wittung P, Kajanus J, Edwards K, Nielsen P, Norde ´n B, et al. (1995)
Phospholipid membrane permeability of peptide nucleic acid. FEBS Lett 365:
27–29.
25. Bendifallah N, Rasmussen FW, Zachar V, Ebbesen P, Nielsen PE, et al. (2006)
Evaluation of cell-penetrating peptides (CPPs) as vehicles for intracellular
delivery of antisense peptide nucleic acid (PNA). Bioconjugate Chem 17:
750–758.
26. Braun K, Peschke P, Pipkorn R, Lampel S, Wachsmuth M, et al. (2002) A
biological transporter for the delivery of peptide nucleic acids (PNAs) to the
nuclear compartment of living cells. J Mol Biol 318: 237–243.
27. Cutrona G, Carpaneto EM, Ulivi M, Roncella S, Landt O, et al. (2000) Effects
in live cells of a c-myc anti-gene PNA linked to a nuclear localization signal. Nat
Biotechnol 18: 300–303.
28. Hu J, Corey DR (2007) Inhibiting gene expression with peptide nucleic acid
(PNA)–peptide conjugates that target chromosomal DNA. Biochemistry 46:
7581–7589.
29. Shiraishi T, Bendifallah N, Nielsen PE (2006) Cellular delivery of polyheter-
oaromate-peptide nucleic acid conjugates mediated by cationic lipids. Bioconju-
gate Chem 17: 189–194.
30. Shiraishi T, Pankratova S, Nielsen PE (2005) Calcium ions effectively enhance
the effect of antisense peptide nucleic acids conjugated to cationic tat and
oligoarginine peptides. Chem Biol 12: 923–929.
31. Dragulescu-Andrasi A, Rapireddy S, He G, Bhattacharya B, Hyldig-Nielsen JJ,
et al. (2006) Cell-permeable peptide nucleic acid designed to bind to the 59-
untranslated region of E-cadherin transcript induces potent and sequence-
specific antisense effects. J Amer Chem Soc 128: 16104–16112.
32. Mukherjee S, Abd-El-Latif M, Bronstein M, Ben-nun-Shaul O, Kler S, et al.
(2007) High cooperativity of the SV40 major capsid protein VP1 in virus
assembly. PLoS ONE 2: e765.
33. Salunke DM, Caspar DLD, Garcea RL (1986) Self-assembly of purified
polyomavirus capsid protein VP1. Cell 46: 895–904.
34. Kimchi-Sarfaty C, Brittain S, Garfield S, Caplen NJ, Tang QQ, et al. (2005)
Efficient delivery of RNA interference effectors via in vitro-packaged SV40
pseudovirions. Hum Gene Ther 16: 1110–1115.
35. Kimchi-Sarfaty C, Vieira WD, Dodds D, Sherman A, Kreitman RJ, et al. (2006)
SV40 Pseudovirion gene delivery of a toxin to treat human adenocarcinomas in
mice. Cancer Gene Ther 13: 648–657.
36. Ueda K, Pastan I, Gottesman MM (1987) Isolation and sequence of the
promoter region of the human multidrug-resistance (P-glycoprotein) gene. J Biol
Chem 262: 17432–17436.
37. Cogoi S, Codognotto A, Rapozzi V, Meeuwenoord N, van der Marel G, et al.
(2005) Transcription inhibition of oncogenic KRAS by a mutation-selective
peptide nucleic acid conjugated to the PKKKRKV nuclear localization signal
peptide. Biochemistry 44: 10510–10519.
38. Turner JJ, Ivanova GD, Verbeure B, Williams D, Arzumanov AA, et al. (2005)
Cell-penetrating peptide conjugates of peptide nucleic acids (PNA) as inhibitors
of HIV-1 Tat-dependent trans-activation in cells. Nucleic Acids Res 33:
6837–6849.
39. Abes S, Williams D, Prevot P, Thierry A, Gait MJ, et al. (2006) Endosome
trapping limits the efficiency of splicing correction by PNA-oligolysine
conjugates. J Control Release 110: 595–604.
40. Cordelier P, Morse B, Strayer DS (2003) Targeting CCR5 with siRNAs: using
recombinant SV40-derived vectors to protect macrophages and microglia from
R5-tropic HIV. Oligonucleotides 13: 281–294.
41. Kimchi-Sarfaty C, Ben-Nun-Shaul O, Rund D, Oppenheim A, Gottesman MM
(2002) In vitro-packaged SV40 pseudovirions as highly efficient vectors for gene
transfer. Hum Gene Ther 13: 299–310.
42. Guo H, Zhang QL, Zhang J, Wang CW, Kong JX, et al. (2005) [Inhibition of
multidrug resistance related P-gp expression in human neuroblastoma by
antisense peptide nucleic acid]. Acta Acad Med Sinicae 27: 300–304.
43. Wei HL, Wu YJ, Jing T, Bai DC, Ma LF (2003) Sensitization and apoptosis
augmentation of K562/ADM cells by anti-multidrug resistance gene peptide
nucleic acid and antisense oligodeoxyribonucleotide. Acta Pharmacol Sinica 24:
805–811.
44. Kimchi-Sarfaty C, Alexander NS, Brittain S, Ali S, Gottesman MM (2004)
Transduction of multiple cell types using improved conditions for gene delivery
and expression of SV40 pseudovirions packaged in vitro. Biotechniques 37:
270–275.
45. Strayer DS, Pomerantz RJ, Yu M, Rosenzweig M, BouHamdan M, et al. (2000)
Efficient gene transfer to hematopoietic progenitor cells using SV40-derived
vectors. Gene Ther 7: 886–895.
46. Akiyama S, Fojo A, Hanover JA, Pastan I, Gottesman MM (1985) Isolation and
genetic characterization of human KB cell lines resistant to multiple drugs.
Somat Cell Molec Gen 11: 117–126.
47. Koch T (2004) PNA Synthesis by Boc Chemistry. In: Neilsen P, ed. Peptide
Nucleic Acids: Protocols & Applications (2nd edition). Wymondham, UK:
Horizon Bioscience. pp 37–60.
48. Pokorski JK, Witschi MA, Purnell BL, Appella DH (2004) (S,S)-trans-
cyclopentane-constrained peptide nucleic acids. A general backbone modifica-
tion that improves binding affinity and sequence specificity. J Amer Chem Soc
126: 15067–15073.
Inhibiting Multidrug Resistance by PNAs
PLoS ONE | www.plosone.org 6 March 2011 | Volume 6 | Issue 3 | e17981